Streetbeat News

DNA

Ginkgo Bioworks Holdings, Inc.

https://www.ginkgobioworks.com

Industry

Biotechnology

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Open

7.21

Mkt cap

367M

Volume

High

7.21

P/E Ratio

-0.35

52-wk high

75.20

Low

6.01

Div yield

N/A

52-wk low

5.26

Ginkgo Bioworks and SaponiQx, a subsidiary of Agenus Inc (NASDAQ: AGEN), have been awarded a 5-year contract by the MCDC, worth up to $31M, to discover and manufacture next-generation vaccine adjuvants using generative molecular design.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 12:10 pm

Cathie Wood's Ark Invest purchased over $11 million worth of Tesla Inc (TSLA) shares, demonstrating confidence in the electric vehicle company despite market fluctuations. The firm also sold over $4.5 million in Nvidia Corp (NVDA) shares, aligning with Wood's preference for Tesla as a top AI investment over Nvidia. Additionally, Ark Invest adjusted its portfolio by selling Shopify Inc (SHOP) shares, and increasing investments in biotech firms Intellia Therapeutics Inc (NTLA) and Ginkgo Bioworks Holdings Inc (DNA), as well as in Robinhood Markets Inc (HOOD) and Spotify Technology SA (SPOT).

Portfolio Pulse from Benzinga Neuro

February 06, 2024 | 3:45 am

Ark Invest, led by Cathie Wood, has purchased $3.3 million worth of Robinhood Markets Inc (HOOD) shares and continued its investment in Tesla Inc (TSLA) with a $1.24 million purchase. The firm also sold shares in Twilio Inc (TWLO) and UiPath Inc (PATH), while investing in Ginkgo Bioworks Holdings Inc (DNA) and Teradyne Inc (TER). Ark's strategy reflects confidence in Robinhood's financial strategy and Tesla's long-term value, despite recent setbacks.

Portfolio Pulse from Benzinga Neuro

February 01, 2024 | 3:55 am

Ginkgo Bioworks Holdings (NYSE:DNA) has received mixed reviews from financial analysts, with 2 bearish and 2 indifferent ratings in the past quarter. The average 12-month price target is $1.8, up from the previous $1.25, with a high estimate of $2.50 and a low of $1.10. Goldman Sachs analyst Matthew Sykes lowered the price target to $1.10 from $1.25, maintaining a 'Sell' rating, while Raymond James analyst Rahul Sarugaser announced a 'Market Perform' rating with a $2.50 target. Ginkgo Bioworks faces challenges with a -16.52% revenue decline, a net margin of -546.44%, and an ROE of -21.98%, but maintains a low debt-to-equity ratio of 0.32.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 4:00 pm

Goldman Sachs analyst Matthew Sykes has maintained a Sell rating on Ginkgo Bioworks Holdings (NYSE:DNA) and reduced the price target from $1.25 to $1.1.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 2:00 pm

U.S. stocks traded higher on Monday, with notable gains in several companies. NuStar Energy L.P. (NS) surged after Sunoco's acquisition announcement. Other stocks like Sagimet Biosciences (SGMT), Rumble (RUM), Digital World Acquisition Corp (DWAC), and Fastly (FSLY) also saw significant increases due to various positive news, including clinical trial results, partnerships, and analyst upgrades.

Portfolio Pulse from Avi Kapoor

January 22, 2024 | 3:45 pm

Goldman Sachs analyst Matthew Sykes has maintained a Sell rating on Ginkgo Bioworks Holdings (NYSE:DNA) and reduced the price target from $1.25 to $1.1.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 12:43 pm

Ark Invest, led by Cathie Wood, sold 229,215 shares of DraftKings Inc (DKNG) valued at $8.04 million through its ARK Innovation ETF (ARKK). This move indicates a shift in strategy, as DraftKings was previously a key holding for Ark. The firm also made significant investments in biotech firms, buying shares of Recursion Pharmaceuticals (RXRX), CRISPR Therapeutics AG (CRSP), and Ginkgo Bioworks Holdings Inc (DNA) through ARKK and ARK Genomic Revolution ETF (ARKG).

Portfolio Pulse from Benzinga Neuro

January 18, 2024 | 4:09 am

Concentric by Ginkgo, a unit of Ginkgo Bioworks (NYSE:DNA), has partnered with Illumina, Inc. (NASDAQ:ILMN) to expand global biosecurity capabilities. They plan to set up a pathogen monitoring network using Illumina's DNA sequencing technology. This 'bioradar' system will help detect and respond to biological threats, supporting global health objectives. The co-marketing agreement aims to enhance pathogen genomic surveillance and build local biosurveillance capacity, reducing reliance on third-party biosecurity services.

Portfolio Pulse from Benzinga Newsdesk

January 15, 2024 | 11:24 pm

Ginkgo Bioworks' stock is trading lower following the company's announcement that its preliminary unaudited Cell Engineering revenue for 2023 is expected to be within the previously disclosed guidance range of $145 – $150 million.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 8:24 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.